Credit: Shutterstock photoThe founder of Hayman Advisors Kyle Bass made a fortune during the sub-prime crisis, and today he does not like Japan and likes structured mortgages, housing, gold and U.S. stocks. His U.S. portfolio contains eight stocks - one of them new. With seven stocks sold out, his portfolio had 47% quarter-over-quarter turnover and a value of $165 million.
The new position is a company called ZIOPHARM Oncology Inc. ( ZIOP ). Bass bought 316,987 shares at an average price of $4. He also bought and sold a smaller parcel of shares of the company in the first and second quarter of 2012.
ZIOPHARM Oncology Inc. is a Delaware Corporation. It is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. The drug in the latest stage is Palifosfamide (ZIO-201) which is a type of drug called alkylating agents that binds to cancer cell DNA to halt tumor growth. It is currently in Phase 3 studies.
Ziopharm Oncology Inc. has a market cap of $144.6 million; its shares were traded around $1.76 with and P/S ratio of 176.50.
Other Gurus who bought the stock in the fourth quarter include: Jean-Marie Eveillard , Paul Tudor Jones and Steven Cohen .
See Kyle Bass' portfolio here. Also check out the Undervalued Stocks, Top Growth Companies and High Yield stocks of Kyle Bass.About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
